[go: up one dir, main page]

CA2094266A1 - Formulations - Google Patents

Formulations

Info

Publication number
CA2094266A1
CA2094266A1 CA 2094266 CA2094266A CA2094266A1 CA 2094266 A1 CA2094266 A1 CA 2094266A1 CA 2094266 CA2094266 CA 2094266 CA 2094266 A CA2094266 A CA 2094266A CA 2094266 A1 CA2094266 A1 CA 2094266A1
Authority
CA
Canada
Prior art keywords
beclomethasone
dipropionate
aerosol formulations
heptafluoropropane
tetrafluoroethane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2094266
Other languages
English (en)
Other versions
CA2094266C (fr
Inventor
Robert K. Schultz
David W. Schultz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24400688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2094266(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2094266A1 publication Critical patent/CA2094266A1/fr
Application granted granted Critical
Publication of CA2094266C publication Critical patent/CA2094266C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Formulations d'aérosol de solution pharmaceutique comprenant béclométhasone 17,21 dipropionate, éthanol ainsi qu'un propulseur choisi dans le groupe constitué de 1,1,1,2-tétrafluoroéthane, 1,1,1,2,3,3,3-heptafluoropropane, ainsi qu'un mélange de ceux-ci.
CA002094266A 1990-10-18 1991-10-09 Formulations Expired - Lifetime CA2094266C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59969490A 1990-10-18 1990-10-18
US599,694 1990-10-18
PCT/US1991/007574 WO1992006675A1 (fr) 1990-10-18 1991-10-09 Formulation d'aerosol contenant du beclomethasone 17,21 dipropionate

Publications (2)

Publication Number Publication Date
CA2094266A1 true CA2094266A1 (fr) 1992-04-19
CA2094266C CA2094266C (fr) 1999-06-01

Family

ID=24400688

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002094266A Expired - Lifetime CA2094266C (fr) 1990-10-18 1991-10-09 Formulations

Country Status (12)

Country Link
EP (1) EP0553298B1 (fr)
JP (2) JP2769925B2 (fr)
AT (1) ATE114112T1 (fr)
AU (1) AU658854B2 (fr)
BR (1) BR1100339A (fr)
CA (1) CA2094266C (fr)
DE (1) DE69105212T2 (fr)
DK (1) DK0553298T3 (fr)
ES (1) ES2064160T3 (fr)
HK (1) HK130397A (fr)
NZ (1) NZ240237A (fr)
WO (1) WO1992006675A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220403B2 (en) 1999-09-11 2007-05-22 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
DE4123663A1 (de) * 1991-07-17 1993-01-21 Schwabe Willmar Gmbh & Co Aerosol-zubereitung und verwendung eines treibmittels dafuer
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
CA2421976C (fr) 1991-12-12 2004-04-20 Glaxo Group Limited Medicaments
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
ATE128350T1 (de) * 1991-12-12 1995-10-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung.
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
MX9304585A (es) 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
US5833950A (en) * 1992-07-31 1998-11-10 Glaxo Group Limited Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate
US5593661A (en) * 1993-03-29 1997-01-14 Henry; Richard A. Lidocaine aerosol anaesthetic
CA2178473C (fr) * 1993-12-20 2004-08-24 Tsi-Zong Tzou Compositions d'aerosols a base de flunisolide
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5653961A (en) * 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
CZ288337B6 (en) 1995-06-27 2001-05-16 Boehringer Ingelheim Kg Pharmaceutical preparation
DE19616573C2 (de) 1996-04-25 1999-03-04 Pari Gmbh Verwendung unterkritischer Treibmittelmischungen und Aerosole für die Mikronisierung von Arzneimitteln mit Hilfe dichter Gase
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
JPH1067655A (ja) * 1996-08-23 1998-03-10 Nippon Hoechst Marion Roussel Kk 喘息治療用エアゾール剤
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
CA2273835A1 (fr) * 1996-12-04 1998-06-11 Bioglan Ireland (R & D) Limited Compositions pharmaceutiques et leurs dispositifs d'administration
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
GB2326334A (en) † 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
GB2332372B (en) * 1997-12-08 2002-08-14 Minnesota Mining & Mfg Pharmaceutical aerosol compositions
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
US6264923B1 (en) 1998-05-13 2001-07-24 3M Innovative Properties Company Medicinal aerosol formulation of ciclesonide and related compounds
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
IT1303788B1 (it) 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
WO2001047493A1 (fr) * 1999-12-24 2001-07-05 Glaxo Group Limited Formulation pharmaceutique en aerosol de salmeterol et de propionate de fluticasone
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
FR2813877B1 (fr) 2000-09-11 2002-12-06 Cezus Cie Europ Du Zirconium Procede de separation de metaux tels que le zirconium et l'hafnium
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
ES2364636T3 (es) 2001-12-19 2011-09-08 Novartis Ag Administración pulmonar de aminoglucósidos.
EP1340503A1 (fr) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Formule d'une solution pour aerosol contenant des dérivés d'esters de 3,17 estratrien pour administration pulmonale
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
KR20100055542A (ko) 2002-06-25 2010-05-26 애크럭스 디디에스 피티와이 리미티드 비정질 약학적 조성물을 이용한 경피전달속도의 제어
AUPS317302A0 (en) * 2002-06-25 2002-07-18 Drug Delivery Solutions Pty Ltd Metastable pharmaceutical compositions
CA2528479A1 (fr) 2003-06-13 2004-12-23 Altana Pharma Ag Combinaison de formoterol et de ciclesonide
US8371292B2 (en) 2003-09-16 2013-02-12 Nycomed Gmbh Use of ciclesonide for the treatment of respiratory diseases
DK2425820T3 (en) 2007-02-11 2015-07-13 Map Pharmaceuticals Inc A method for the therapeutic administration of DHE in order to enable quick relief of migraine, while minimizing the adverse event profile
US8652443B2 (en) 2008-02-14 2014-02-18 Precision Dermatology, Inc. Foamable microemulsion compositions for topical administration
AR079451A1 (es) 2009-12-18 2012-01-25 Nycomed Gmbh Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
DK2627386T3 (en) 2010-10-12 2015-05-26 Ivax Pharmaceuticals Ireland Nose spray interior
EP2721036B1 (fr) 2011-06-15 2015-07-22 Takeda GmbH Nouveaux composés de 3,4,4a,10b-tétrahydro-1h-thiopyrano[4,3-c]isoquinoline
US20140112945A1 (en) 2011-06-17 2014-04-24 Takeda Gmbh Novel phthalazinone-pyrrolopyrimidinecarboxamide derivatives
CA2844944A1 (fr) * 2011-08-18 2013-02-21 Takeda Gmbh Produit aerosol pharmaceutique pour l'administration par inhalation orale ou nasale
US9480688B2 (en) 2011-09-20 2016-11-01 Sergeant's Pet Care Products, Inc. Pheromone compositions and their use to modify behavior in different vertebrate species
WO2013043896A1 (fr) * 2011-09-20 2013-03-28 Sergeant's Pet Care Products, Inc. Compositions d'interomone et leur utilisation pour modifier le comportement chez différentes espèces vertébrées
WO2018069210A1 (fr) 2016-10-10 2018-04-19 Takeda Gmbh Tétrahydrofuro [3,4-c] isoquinolines en tant qu'inhibiteurs de pde4
US20200268706A1 (en) * 2017-02-27 2020-08-27 Gregory LEVITIN Combination of furosemide and steroids and application system therefor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8432063D0 (en) * 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
DE4003270A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgase und ihre verwendung in arzneimittelzubereitungen
IL97065A (en) * 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
DE4003272A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220403B2 (en) 1999-09-11 2007-05-22 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate

Also Published As

Publication number Publication date
BR1100339A (pt) 2000-07-18
JPH10182467A (ja) 1998-07-07
EP0553298B1 (fr) 1994-11-17
JPH06501710A (ja) 1994-02-24
WO1992006675A1 (fr) 1992-04-30
DE69105212D1 (de) 1994-12-22
AU9087391A (en) 1992-05-20
DK0553298T3 (da) 1995-04-18
EP0553298A1 (fr) 1993-08-04
NZ240237A (en) 1994-06-27
ES2064160T3 (es) 1995-01-16
HK130397A (en) 1997-09-19
JP2769925B2 (ja) 1998-06-25
ATE114112T1 (de) 1994-12-15
CA2094266C (fr) 1999-06-01
DE69105212T2 (de) 1995-03-23
AU658854B2 (en) 1995-05-04

Similar Documents

Publication Publication Date Title
CA2094266A1 (fr) Formulations
CA2178473A1 (fr) Compositions d'aerosols a base de flunisolide
EP1277467A3 (fr) Formulations d' aérosols sans chlorofluorohydrocarbures
GR3037046T3 (en) Non-chlorofluorocarbon aerosol formulations.
AU3038197A (en) Aerosol formulations
AU709052C (en) Suspension aerosol formulations
CA2381329A1 (fr) Medicaments
AU5306486A (en) Drug-containing chlorofluorocarbon aerosol propellent formulations
NO980858D0 (no) Farmasöytiske preparater og anordninger for administrering derav
ZA943648B (en) Medicament aerosol formulation based on fusafungine a process for its preparation and pharmaceutical compositions containing it
MX9707238A (es) Formulaciones en aerosol de butixocort.
AU1534501A (en) Pharmaceutical formulations of salmeterol
CA2141039A1 (fr) Formulations d'aerosol exemptes de surfactif, renfermant du dipropionate de beclomethasone

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry